Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) EBIT (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of EBIT readings, the most recent being -$2.1 million for Q4 2017.

  • On a quarterly basis, EBIT rose 44.02% to -$2.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$13.1 million, a 26.24% increase, with the full-year FY2025 number at -$45.6 million, down 507.11% from a year prior.
  • EBIT hit -$2.1 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$932000.0 in Q2 2016 to a low of -$13.3 million in Q1 2015.
  • Median EBIT over the past 5 years was -$5.7 million (2013), compared with a mean of -$6.0 million.
  • Biggest five-year swings in EBIT: soared 89.62% in 2016 and later tumbled 615.24% in 2017.
  • Eledon Pharmaceuticals' EBIT stood at -$5.5 million in 2013, then dropped by 12.83% to -$6.3 million in 2014, then plummeted by 76.84% to -$11.1 million in 2015, then soared by 66.04% to -$3.8 million in 2016, then soared by 44.02% to -$2.1 million in 2017.
  • The last three reported values for EBIT were -$2.1 million (Q4 2017), -$3.0 million (Q3 2017), and -$6.7 million (Q2 2017) per Business Quant data.